Inovio Pharmaceuticals Will Independently Develop Prostate Cancer Immunotherapy

Inovio Pharmaceuticals Will Independently Develop Prostate Cancer Immunotherapy
shutterstock_176547491Inovio Pharmaceuticals, Inc. has announced that it has finished a 2013 licensing agreement with Roche to co-develop INO-5150, Inovio’s investigational drug targeting prostate cancer. Furthermore, both companies will no longer collaborate in prostate cancer research. Importantly, all the rights that Roche held towards INO-5150 will be returned to Inovio, which will independently continue with a Phase I clinical trial to test the drug in the beginning of 2015. Nonetheless, both companies will remain in collaboration to develop Inovio's DNA immunotherapy (INO-1800) against hepatitis B virus. INO-5150 is a dual-antigen synthetic DNA immunotherapy directed towards the prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA). Previous studies using animal models have shown that vaccination with the drug could efficiently produce a strong T-cell immune response, the highest verified so far in a PSA-targeting immunotherapy. "The Inovio/Roche partnership will continue to thrive focusing on the development of INO-1800 for the treatment of hepatitis B. In addition to recently demonstrating clinical efficacy and the ability to induce potent antigen specific CD8+ T cell responses in our VGX-3100 phase II study, Inovio will be moving a broad portfolio of immuno-oncology products through development, including INO-311
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *